Kids Flyer Reference List
Fact One: Children aged 12-15 years are competent to consent to vaccination without parental permission – according to the Ministry of Health and the Immunisation Advisory Centre (IMAC).
Fact Two: Pfizer’s “COVID-19 Vaccine” is an experimental gene therapy still in clinical trials – including for children.
“The safety evaluation in Study C4591001 is ongoing.”
https://medsafe.govt.nz/profs/Datasheet/c/comirnatyinj.pdf
“11. Deferred pediatric study C4591001 to evaluate the safety and effectiveness of COMIRNATY in children 12 years through 15 years of age
- Final Protocol Submission: October 7, 2020
- Study Completion: May 31, 2023
- Final Report Submission: October 31, 2023
12. Deferred pediatric study C4591007 to evaluate the safety and effectiveness of COMIRNATY in children 6 months to <12 years of age
- Final Protocol Submission: February 8, 2021
- Study Completion: November 30, 2023
- Final Report Submission: May 31, 2024
13. Deferred pediatric study C4591023 to evaluate the safety and effectiveness of COMIRNATY in infants <6 months of age
- Final Protocol Submission: January 31, 2022
- Study Completion: July 31, 2024
- Final Report Submission: October 31, 2024″
https://www.fda.gov/media/151733/download
The Ministry of Health says:
“[Adult] Participants had two doses of the vaccine or placebo, getting their second dose within 19 to 42 days after their first dose. They were then closely monitored and evaluated for at least 2 months after their second dose.”
The CDC says the FDA gave the Pfizer-BioNTech COVID-19 vaccine emergency authorization to use in children ages 5-15 years old and full approval to use in people ages 16 years and older. Nov 4, 2021
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html
https://worldcouncilforhealth.org/resources/covid-vaccine-for-children/
From the American Society of Gene + Cell Therapy: “Today’s FDA approval of the COVID-19 vaccine BNT162b2 from Pfizer and BioNTech marks a great day for the USA and a significant milestone for the field of gene and cell therapy.
Not only will this vaccine be a critical step in protecting people from a virus that has killed more than 1.5 million people and overwhelmed hospital systems worldwide. It is the first-ever mRNA vaccine or drug approved by the FDA, representing a culmination of decades of research that now demonstrates the safety and efficacy of gene therapy on the world’s stage.”
https://asgct.org/research/news/december-2020/pfizer-covid19-mrna-vaccine
Fact Three: The Pfizer COVID-19 vaccine does NOT prevent a person from catching or passing on the SARS-CoV-2 virus.
“Vaccination reduces the risk of delta variant infection and accelerates viral clearance. Nonetheless, fully vaccinated individuals with breakthrough infections have peak viral load similar to unvaccinated cases and can efficiently transmit infection in household settings, including to fully vaccinated contacts.”
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00648-4/fulltext
“You can still get COVID-19 if you’re vaccinated but the symptoms are likely to be very mild, or you may not have any symptoms at all. This means that if you are vaccinated and get COVID-19, you may not realise and spread it to others.”
https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-health-advice-public/assessment-and-testing-covid-19/covid-19-saliva-testing
“Thinking that we’ll be able to achieve some kind of threshold where there’ll be no more transmission of infections may not be possible,” Jones acknowledged last week to members of a panel that advises the CDC on vaccines.
Vaccines have been quite effective at preventing cases of COVID-19 that lead to severe illness and death, but none has proved reliable at blocking transmission of the virus, Jones noted. Recent evidence has also made clear that the immunity provided by vaccines can wane in a matter of months.
The result is that even if vaccination were universal, the coronavirus would probably continue to spread.
“We would discourage” thinking in terms of “a strict goal,” he said.”
“People who have a condition or are taking medications that weaken their immune system may not be fully protected even if they are fully vaccinated. They should continue to take all precautions recommended for unvaccinated people, including wearing a well-fitted mask, until advised otherwise by their healthcare provider.
If you are fully vaccinated, to maximize protection from the Delta variant and prevent possibly spreading it to others, wear a mask indoors in public if you are in an area of substantial or high transmission.”
https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html
“A vaccine breakthrough infection happens when a fully vaccinated person gets infected with COVID-19. People with vaccine breakthrough infections may spread COVID-19 to others.”
“There is a chance you might still get or spread COVID-19 even if you have a vaccine, so it’s important to follow advice about how to avoid catching and spreading COVID-19.”
https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/
Fact Four: Reactions to the vaccine are common and serious adverse events are having devastating, and likely life-long, effects.
Medsafe vaccine reaction data:
https://www.medsafe.govt.nz/COVID-19/vaccine-report-overview.asp
https://www.medsafe.govt.nz/COVID-19/safety-report-35.asp
“In children aged 12-15 years, “There is evidence of an association between mRNA COVID-19 vaccines and myocarditis. This is an extremely rare adverse event. The medium- to long-term effects are unknown and long-term follow-up is being conducted.
“As longer-term data on potential adverse reactions accumulates, greater certainty may allow for a reconsideration of the benefits and harms. This data may not be available for several months,” says the UK Joint Committee on Vaccination and Immunisation.”
Fact Five: Heart inflammation (myocarditis), a serious vaccine reaction, is never mild in children, despite the Ministry’s assurance.
“Myocarditis is a condition where the muscular walls of the heart become inflamed. Myocarditis typically results in poor heart function.
The inflammatory process begins when the body’s immune cells (the cells that fight infection) actually penetrate the heart tissue. These immune cells become activated and produce chemicals that can cause damage to the heart muscle cells. There is thickening and swelling of the heart muscle. All four chambers of the heart may be affected and become enlarged.
Damaged muscle cells may heal over time or there may be cell death followed by scar formation. If this process is extensive and a large portion of the heart is involved, the heart’s ability to pump blood is impaired.
As a result, the key organs and tissues in the body do not get enough oxygen and nutrients and cannot get rid of waste products. This is often referred to as congestive heart failure.
It is not unusual for someone who has severe myocarditis to suffer from other problems such as liver or kidney failure, as well.
The good news is that about two-thirds of the children, with the right medical management, will have a complete recovery.
If untreated, only 10 percent to 20 percent will have recovery on their own, and 80 percent will develop chronic heart disease. For most children, recovery usually occurs within two to three months from the onset of the illness.
Of the remaining one-third who are treated, 10 percent to 20 percent will improve but have chronic residual heart problems called “dilated cardiomyopathy.”
This is a condition where the heart has become enlarged and may have diminished function or residual heart failure. In this case, the child will need long-term follow-up by a cardiologist. Sometimes these children will develop progressive heart failure and need a heart transplant.”
https://www.cincinnatichildrens.org/health/m/myocarditis
“Myocarditis in children challenges the practitioner on every front, from the appropriate diagnostic workup to the aggressiveness of intervention and the type and extent of follow-up after recovery. Many patients have spontaneous recovery, and just as many will sustain irreversible myocardial injury, sometimes pressing the practitioner to make medical decisions without a confirmed diagnosis or decisions on therapy that are not evidence based. Myocarditis in children shares features with that in adults, such that a supplemental section on the adult perspective highlights some of these major similarities and differences. However, given its distinct characteristics in children and the potential impact on their lifelong health, the American Heart Association commissioned this statement to provide guidance on its management specific to the pediatric population.
Myocarditis in children remains a challenging condition to diagnose and manage. Its impact on lifelong morbidity and mortality is significant. To improve its outcomes, more scientifically rigorous investigation is needed.”
https://www.ahajournals.org/doi/10.1161/CIR.0000000000001001
“After treatment, many patients live long, full lives free from the effects of myocarditis. For others, however, ongoing cardiovascular medication or even a heart transplant may be needed. Overall, myocarditis which can cause dilated cardiomyopathy, are thought to account for up to 45 percent of heart transplants in the U.S. today.”
https://www.myocarditisfoundation.org/about-myocarditis/
“Cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) have been reported after Pfizer-BioNTech COVID-19 vaccination of children ages 12–17 years. These reactions are rare; in one study, the risk of myocarditis after the second dose of Pfizer-BioNTech in the week following vaccination was around 54 cases per million doses administered to males ages 12–17 years.”
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html
Fact Six: Children have a vanishingly LOW risk of becoming seriously ill with COVID-19.
“It is clear that children are at very low risk of spreading the infection to other children, of spreading to adults as seen in household transmission studies, or of taking it home or becoming ill, or dying — this is settled scientific global evidence ((references 1, 2, 3, 4).”
https://childrenshealthdefense.org/defender/vaccinate-children-covid-natural-exposure-immunity/
“COVID-19 generally has milder effects in children than adults and is rarely severe or fatal. Adolescents who have COVID-19 will commonly have no symptoms or only mild symptoms, similar to a cold.”
Dr. Geert Vanden Bossche writes that children’s innate immunity:
“… normally/ naturally largely protects them and provides a kind of herd immunity in that it dilutes infectious CoV pressure at the level of the population, whereas mass vaccination turns them into shedders of more infectious variants. Children/ youngsters who get the disease mostly develop mild to moderate disease and as a result continue to contribute to herd immunity by developing broad and long-lived immunity.”
https://www.geertvandenbossche.org/post/the-keys-to-unlock-the-golden-gate-of-herd-immunity-towards-sars-cov-2
https://worldcouncilforhealth.org/resources/covid-vaccine-for-children/
Fact Seven: COVID-19 in children is almost always a mild, flu-like illness, from which 99.998% recover.
UK’s Joint Committee on Vaccination and Immunisation says here on September 3, 2021: “For the vast majority of children, SARS-CoV-2 infection is asymptomatic or mildly symptomatic and will resolve without treatment. Of the very few children aged 12 to 15 years who require hospitalisation, the majority have underlying health conditions.
“Given the very low risk of serious COVID-19 disease in otherwise healthy 12 to 15 year olds, considerations on the potential harms and benefits of vaccination are very finely balanced and a precautionary approach was agreed.”
“Infection fatality ratio (Estimated number of deaths per 1,000,000 infections).
Scenario 5: Current Best Estimate
0–17 years old: 20″
https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html
“Children ages 5 to 11 are at extremely low risk of death from coronavirus. For instance, in a meta-analysis combining data from five studies, Stanford researchers Cathrine Axfors and John Ioannidis found a median infection fatality rate (IFR) of 0.0027% in children ages 0-19. In children ages 5 to 11, the IFR is even lower.”
Fact Eight: Since 2000 Pfizer has paid over $4.6 billion in fines and settlements for criminal, misleading and deceptive conduct.
Back Of Flyer
HOW SERIOUS IS COVID-19 FOR CHILDREN?
NZ’s Starship Hospital says COVID-19 still appears to remain mostly a mild and/or asymptomatic disease in younger children.
“COVID-19 still appears to remain mostly a mild and/or asymptomatic disease in younger children.”
https://starship.org.nz/guidelines/covid-19-vaccination-in-children/
The UK’s Joint Committee on Vaccination and Immunisation says that for the vast majority of children, SARS-CoV-2 infection is asymptomatic or mildly symptomatic and will resolve without treatment.
According to the USA’s Centers for Disease Control and Prevention, the survival rate of children aged from birth to 17 years old is 99.998%.
“Infection fatality ratio (Estimated number of deaths per 1,000,000 infections).
Scenario 5: Current Best Estimate
0–17 years old: 20″
https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html
“Children ages 5 to 11 are at extremely low risk of death from coronavirus. For instance, in a meta-analysis combining data from five studies, Stanford researchers Cathrine Axfors and John Ioannidis found a median infection fatality rate (IFR) of 0.0027% in children ages 0-19. In children ages 5 to 11, the IFR is even lower.”
CAN VACCINATED CHILDREN PASS ON THE VIRUS TO ADULTS, AND VICE VERSA?
The USA’s Centers for Disease Control and Prevention says a fully vaccinated person can still get infected with COVID-19 and may spread COVID-19 to others.
According to a recent study in The Lancet medical journal (October 29, 2021), the vaccine’s effect on reducing transmission is minimal in the context of Delta variant circulation.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00648-4/fulltext
“While the data is clear that vaccines protect people from the effects of COVID-19, research is ongoing to determine whether a vaccinated person could still transmit the virus to someone else – so to be safe, we must assume there is still a risk of transmission.“
HOW SAFE IS THE “VACCINE” FOR CHILDREN?
The UK’s Joint Committee on Vaccination and Immunisation has assessed that the risks to children outweigh the benefits at this time.
Professor Wei Shen Lim, Chair of COVID-19 Immunisation for the JCVI, said:
“Children aged 12 to 15 years old with underlying health conditions that put them at higher risk of severe COVID-19 should be offered COVID-19 vaccination. The range of underlying health conditions that apply has recently been expanded.
“For otherwise healthy 12 to 15 year old children, their risk of severe COVID-19 disease is small and therefore the potential for benefit from COVID-19 vaccination is also small. The JCVI’s view is that overall, the health benefits from COVID-19 vaccination to healthy children aged 12 to 15 years are marginally greater than the potential harms.
“Taking a precautionary approach, this margin of benefit is considered too small to support universal COVID-19 vaccination for this age group at this time. The committee will continue to review safety data as they emerge.“
Furthermore, Pfizer’s Comirnaty COVID-19 Vaccine lacks long-term safety data, including on children. The trials for safety and efficacy in children will not be completed until the end of 2023 at least.
“The safety evaluation in Study C4591001 is ongoing.”
https://medsafe.govt.nz/profs/Datasheet/c/comirnatyinj.pdf
“11. Deferred pediatric study C4591001 to evaluate the safety and effectiveness of COMIRNATY in children 12 years through 15 years of age
Final Protocol Submission: October 7, 2020
Study Completion: May 31, 2023
Final Report Submission: October 31, 2023
12. Deferred pediatric study C4591007 to evaluate the safety and effectiveness of COMIRNATY in children 6 months to <12 years of age
Final Protocol Submission: February 8, 2021
Study Completion: November 30, 2023
Final Report Submission: May 31, 2024
13. Deferred pediatric study C4591023 to evaluate the safety and effectiveness of COMIRNATY in infants <6 months of age
Final Protocol Submission: January 31, 2022
Study Completion: July 31, 2024
Final Report Submission: October 31, 2024″
https://www.fda.gov/media/151733/download
So far, trials for 12-15-year-olds only followed 660 vaccine recipients for 2 months.
https://medsafe.govt.nz/profs/Datasheet/c/comirnatyinj.pdf (Page 6)
The trial for 5-11-year-olds studied 1,518 children.
https://www.fda.gov/media/153409/download (Page 9)
Pfizer said the clinical development programme was “too small to detect any potential risks of myocarditis [heart inflammation] associated with vaccination”, and that “myocarditis/pericarditis in participants 5-12 years of age will not be studied until AFTER the vaccine is authorised for children”.
https://www.fda.gov/media/153409/download (Page 12)
WHAT ARE THE HEALTH RISKS ASSOCIATED WITH THE JAB?
Mounting evidence in countries expanding emergency use of the vaccine to children aged 5 years and older and young adults, shows a significant number of serious side effects.
These health issues include myocarditis, pericarditis, vaccine-induced thrombotic thrombocytopaenia, related cerebral (head) vein thrombosis (blood clots), and menstruation problems.
Also concerning are paediatric inflammatory multisystem syndrome (PIMS), spike protein-induced autoimmune disease, prion-like encephalitis, antibody-dependent enhancement (ADE), and other potential risks discussed in the medical literature.
Medsafe vaccine reaction data:
https://www.medsafe.govt.nz/COVID-19/vaccine-report-overview.asp
https://www.medsafe.govt.nz/COVID-19/safety-report-35.asp
“In children aged 12-15 years, “There is evidence of an association between mRNA COVID-19 vaccines and myocarditis. This is an extremely rare adverse event. The medium- to long-term effects are unknown and long-term follow-up is being conducted.
“As longer-term data on potential adverse reactions accumulates, greater certainty may allow for a reconsideration of the benefits and harms. This data may not be available for several months,” says the UK Joint Committee on Vaccination and Immunisation.”
https://vaers.hhs.gov/data.html
https://covid-unmasked.net/wp-content/uploads/2021/06/4_5911358343561087210.pdf
https://nzdsos.com/wp-content/uploads/2021/06/Covid-19-Shots-for-Children-from-NZDSOS.pdf
https://nzdsos.com/wp-content/uploads/2021/06/Byram-Bridle.pdf
NEW ZEALAND MEDSAFE’S OFFICIAL SAFETY SIGNALS
Recently Medsafe added “AEFI for children” (Adverse Event Following Immunisation) to their table of : “Summary of investigations into possible safety signals”. As of October 16, a total of 2,738 AEFI reports in children aged 10-19 have been filed.
https://www.medsafe.govt.nz/COVID-19/vaccine-report-overview.asp